Alphabet Soup - Biomarker testing for colon and rectal cancer patients - KRAS, RAS
*C. Bokemeyer, C.-H. Köhne, P. Rougier, C. Stroh, M. Schlichting, E. Van Cutsem
Liver directed therapy – when and how? V. Heinemann Department of Oncology and Comprehensive Cancer Center University of Munich, Germany.
Predictive Biomarkers of EGFR Targeted Therapy: Beyond KRAS
The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.
Impact on Quality of Life of Adding Cetuximab to Irinotecan in Patients Who Have Failed Prior Oxaliplatin-Based Therapy: Results From the EPIC Trial Cathy.
Clinicaloptions.com/oncology Expert Insight Into the First-line Treatment of Metastatic Colorectal Cancer KRAS Status in Response to Cetuximab Retrospective.
Department of GI Medical Oncology Cathy Eng, M.D., F.A.C.P. Associate Professor Associate Medical Director, Colorectal Center Director of Network Clinical.
Keynote lecture 5: Priorities for clinical research in GI cancer Daniel G. Haller, MD Professor of Medicine Abramson Cancer Center and the Perelman School.
Department of GI Medical Oncology
Keynote lecture 5: Priorities for clinical research in GI cancer
